YB-1 Recruits Drosha to Promote Splicing of pri-miR-192 to Mediate the Proangiogenic Effects of H 2 S

Yu Zhou,Xing-Hui Li,Wen-Long Xue,Sheng Jin,Meng-Yao Li,Cai-Cai Zhang,Bo Yu,Lei Zhu,Kun Liang,Ying Chen,Bei-Bei Tao,Yi-Zhun Zhu,Ming-Jie Wang,Yi-Chun Zhu
DOI: https://doi.org/10.1089/ars.2021.0105
2022-04-01
Antioxidants and Redox Signaling
Abstract:<b><i>Aims:</i></b> The genes targeted by miRNAs have been well studied. However, little is known about the feedback mechanisms to control the biosynthesis of miRNAs that are essential for the miRNA feedback networks in the cells. In this present study, we aimed at examining how hydrogen sulfide (H<sub>2</sub>S) promotes angiogenesis by regulating <i>miR-192</i> biosynthesis. <b><i>Results:</i></b> H<sub>2</sub>S promoted <i>in vitro</i> angiogenesis and angiogenesis in Matrigel plugs embedded in mice by upregulating <i>miR-192</i>. Knockdown of the H<sub>2</sub>S-generating enzyme cystathionine γ-lyase (CSE) suppressed <i>in vitro</i> angiogenesis, and this suppression was rescued by exogenous H<sub>2</sub>S donor NaHS. Plakophilin 4 (<i>PKP4</i>) served as a target gene of <i>miR-192</i>. H<sub>2</sub>S up-regulated <i>miR-192 via</i> the VEGFR2/Akt pathway to promote the splicing of primary <i>miR-192</i> (<i>pri-miR-192</i>), and it resulted in an increase in both the precursor- and mature forms of <i>miR-192</i>. H<sub>2</sub>S translocated YB-1 into the nuclei to recruit Drosha to bind with <i>pri-miR-192</i> and promoted its splicing. NaHS treatment promoted angiogenesis in the hindlimb ischemia mouse model and the skin-wound-healing model in diabetic mice, with upregulated <i>miR-192</i> and downregulated PKP4 on NaHS treatment. In human atherosclerotic plaques, <i>miR-192</i> levels were positively correlated with the plasma H<sub>2</sub>S concentrations. <b><i>Innovation and Conclusion:</i></b> Our data reveal a role of YB-1 in recruiting Drosha to splice <i>pri-miR-192</i> to mediate the proangiogenic effect of H<sub>2</sub>S. CSE/H<sub>2</sub>S/YB-1/Drosha/<i>miR-192</i> is a potential therapeutic target pathway for treating diseases, including organ ischemia and diabetic complications. <i>Antioxid. Redox Signal</i>. 36, 760-783. The Clinical Trial Registration number is 2016-224.
biochemistry & molecular biology,endocrinology & metabolism
What problem does this paper attempt to address?